# US 2024/0199544 A1 · Crystalline forms of n,n-dimethyltryptamine and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199544 A1
- Document ID: US20240199544A1
- Status: Published application
- Kind: A1
- Application number: 18/526,500
- Filed: 2023-12-01
- Published: 2024-06-20
- Earliest claimed: 2022-12-01
- Assignees: Atai Therapeutics, Inc.
- Applicants: Atai Therapeutics, Inc.
- Inventors: Majed Fawaz; Setu Kasera
- Web page: https://patentgrep.com/patent/US20240199544A1

## CPC

- C07D 209/16: Tryptamines
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides crystalline forms of N,N-dimethyltryptamine, Also provided herein are methods of using crystalline forms of N,N-DMT and compositions comprising the same, e.g., in the treatment of mental health diseases and/or disorders.

## Claims

### Claim 1

Form IV of N,N-dimethyltryptamine.

### Claim 2 (depends on 1)

Form IV of N,N-dimethyltryptamine of claim 1, characterized by peaks in an X-ray powder diffraction (XRPD) pattern at 13.6±0.2, 20.8±0.2, and 17.80±0.2 °2θ.

### Claim 3 (depends on 2)

The Form IV of N,N-dimethyltryptamine of claims 2, further characterized by at least one XRPD peak selected from 13.9±0.2, 14.0±0.2, 15.4±0.2, 18.6±0.2, 23.6±0.2, 24.5±0.2, 26.0±0.2, or 26.7±0.2 °2θ.

### Claim 4

canceled

### Claim 5

canceled

### Claim 6

canceled

### Claim 7

canceled

### Claim 8

canceled

### Claim 9

canceled

### Claim 10

canceled

### Claim 11

canceled

### Claim 12

canceled

### Claim 13

canceled

### Claim 14 (depends on 1)

The Form IV of N,N-dimethyltryptamine of claim 1, characterized by peaks in an XRPD pattern at 7.7±0.2, 10.4±0.2, 11.9±0.2, 13.0±0.2, 13.6±0.2, 13.9±0.2, 14.0±0.2, 15.2±0.2, 15.4±0.2, 16.2±0.2, 16.9±0.2, 17.5±0.2, 17.8±0.2, 18.1±0.2, 18.6±0.2, 19.3±0.2, 19.8±0.2, 20.8±0.2, 21.1±0.2, 21.6±0.2, 22.4±0.2, 22.7±0.2, 23.6±0.2, 23.8±0.2, 24.5±0.2, 24.8±0.2, 25.2±0.2, 26.1±0.2, 26.7±0.2, 26.9±0.2, 27.5±0.2, 28.0±0.2, 28.2±0.2, 28.6±0.2, 28.8±0.2, 29.3±0.2, 29.5±0.2, 29.6±0.2, 30.2±0.2, 30.4±0.2, 30.6±0.2, 30.9±0.2, 31.1±0.2, 31.6±0.2, 31.9±0.2, 32.8±0.2, 33.2±0.2, 33.7±0.2, 34.5±0.2, and 35.3±0.2 ° 20.

### Claim 15 (depends on 1)

The Form IV of N,N-dimethyltryptamine of claim 1, characterized by an XRPD pattern substantially similar to that shown in FIG. 3.

### Claim 15

canceled

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The Form IV of N,N-dimethyltryptamine of any of claims 1-16, which exhibits a Differential Scanning Calorimetry (DSC) thermogram comprising an endothermic peak at 7015° C.

### Claim 18 (depends on 1)

The Form IV of N,N-dimethyltryptamine of claim 1, which exhibits substantially no weight loss at a temperature under 225±5° C. as measured by thermogravimetric (TGA) analysis.

### Claim 19 (depends on 1)

The Form IV of N,N-dimethyltryptamine of claim 1, having a melting point of 69±5° C.

### Claim 20

Form III of N,N-dimethyltryptamine.

### Claim 21 (depends on 20)

The Form III of N,N-dimethyltryptamine of claim 20, characterized by peaks in an X-ray powder diffraction (XRPD) pattern at 7.6±0.2 and 15.2±0.2.

### Claim 22 (depends on 21)

The Form III of N,N-dimethyltryptamine of claims 21, further characterized by at least one XRPD peak selected from 19.2±0.2 °74, 19.6±0.2, or 23.0±0.2 °2θ.

### Claim 23

canceled

### Claim 24

canceled

### Claim 25

canceled

### Claim 26

canceled

### Claim 27 (depends on 20)

The Form III of N,N-dimethyltryptamine of claim 20, characterized by peaks in an XRPD pattern at 7.6±0.2, 15.2±0.2, 16.8±0.2, 19.2±0.2, 19.6±0.2, 20.0±0.2, 20.4±0.2, 20.7±0.2, 21.5±0.2, 22.4±0.2, 22.9±0.2, 23.1±0.2, 26.3±0.2, 27.1±0.2, 27.8±0.2, 28.5±0.2, 30.7±0.2, and 31.56±0.2 °2θ.

### Claim 28 (depends on 20)

The Form III of N,N-dimethyltryptamine of claims 20, characterized an XRPD pattern substantially similar to that shown in FIG. 2.

### Claim 29

canceled

### Claim 30 (depends on 20)

The Form III of N,N-dimethyltryptamine of claims 20, which exhibits a Differential Scanning Calorimetry (DSC) thermogram comprising an endothermic peak at 44±5° C. when heated at a rate of 10° C./minute.

### Claim 31 (depends on 20)

The Form III of N,N-dimethyltryptamine of claim 20, which exhibits substantially no weight loss at a temperature under 200±5° C. as measured by thermogravimetric (TGA) analysis.

### Claim 32 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The Form III of N,N-dimethyltryptamine ef-any-of claims 20-31, having a melting point of 39±5° C.

### Claim 33

A pharmaceutical composition comprising Form Ill or Form IV of N,N-dimethyltryptamine and a pharmaceutically acceptable excipient.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, comprising Form III of N.N-dimethyltryptamine.

### Claim 35

canceled

### Claim 36

canceled

### Claim 37 (depends on 33)

The pharmaceutical composition of claim 33, comprising Form IV of N.N-dimethyltryptaminefurther.

### Claim 38

canceled

### Claim 39

A method of treating post-traumatic stress disorder (PTSD), depression, or an anxiety disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a Form IV of N,N-dimethyltryptamine, a Form III of N,N-dimethyltryptamine, or a pharmaceutical composition of a Form Ill or a Form IV of N,N-dimethyltryptamine to the subject.

### Claim 40

canceled

### Claim 41

canceled

### Claim 42

canceled
